Aldeyra The
$ 1.54
-3.75%
31 Jul - close price
- Market Cap 92,894,000 USD
- Current Price $ 1.54
- High / Low $ 1.63 / 1.52
- Stock P/E N/A
- Book Value 0.70
- EPS -0.45
- Next Earning Report 2026-08-06
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.22 %
- ROE -0.52 %
- 52 Week High 6.17
- 52 Week Low 1.07
About
Aldeyra Therapeutics, Inc., a biotechnology company, develops and markets drugs for immune-mediated systemic and eye diseases. The company is headquartered in Lexington, Massachusetts.
Analyst Target Price
$6.60
Quarterly Earnings
| Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-05-07 | 2026-02-27 | 2025-11-05 | 2025-08-07 | 2025-05-14 | 2025-02-28 | 2024-11-07 | 2024-08-01 | 2024-05-02 | 2024-03-07 | 2023-11-03 | 2023-08-03 |
| Reported EPS | -0.06 | -0.11 | -0.13 | -0.16 | -0.17 | -0.27 | -0.25 | -0.28 | -0.14 | -0.08 | -0.14 | -0.15 |
| Estimated EPS | -0.12 | -0.155 | -0.17 | -0.21 | -0.244 | -0.22 | -0.26 | -0.14 | -0.11 | -0.14 | -0.25 | -0.3 |
| Surprise | 0.06 | 0.045 | 0.04 | 0.05 | 0.074 | -0.05 | 0.01 | -0.14 | -0.03 | 0.06 | 0.11 | 0.15 |
| Surprise Percentage | 50% | 29.0323% | 23.5294% | 23.8095% | 30.3279% | -22.7273% | 3.8462% | -100% | -27.2727% | 42.8571% | 44% | 50% |
Next Quarterly Earnings
| Jun 2026 | |
|---|---|
| Reported Date | 2026-08-06 |
| Fiscal Date Ending | 2026-06-30 |
| Estimated EPS | -0.11 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: ALDX
2026-07-31 09:09:48
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims against Aldeyra Therapeutics, Inc. (ALDX) on behalf of investors who purchased securities before November 3, 2023, and still hold them. The investigation focuses on whether Aldeyra's officers or directors engaged in corporate wrongdoing. The firm encourages affected shareholders to contact them to learn more about the investigation, noting they operate on a contingency fee basis.
2026-07-30 20:39:55
Aldeyra Therapeutics (NASDAQ: ALDX) has signed a lease for a new corporate headquarters located at 23 Bradford Street, Concord, Massachusetts, encompassing approximately 4,067 square feet. The lease, which commences on September 1, 2026, and runs through September 30, 2029, involves an initial monthly base rent of $12,201.00, escalating annually, in addition to operating expenses and taxes. The company will also provide a $50,000.00 security deposit for the new space.
2026-07-30 05:02:09
Aldeyra Therapeutics Inc (ALDX) currently holds a valuation score of 8.18, placing it 160th out of 384 companies in the Biotechnology & Medical Research industry. The company's P/E ratio is -3.54, which is significantly below its recent high and above its recent low. Important P/B and P/CF data have not yet been disclosed by the company.
2026-07-29 07:02:09
Bronstein, Gewirtz & Grossman, LLC has launched an investigation into potential corporate wrongdoing by Aldeyra Therapeutics, Inc. (ALDX). The firm is encouraging investors who purchased Aldeyra securities before November 3, 2023, and still hold them, to come forward and assist in the investigation. They operate on a contingency fee basis, aiming to recover investor capital and ensure corporate accountability.
2026-07-28 06:11:38
Aldeyra Therapeutics Inc (ALDX) has an institutional shareholding score of 5.00, ranking 132nd in the Biotechnology & Medical Research industry. Institutional shareholding increased by 5.38% quarter-over-quarter, reaching 65.57%. Knoll Capital Management, LLC is the largest reported institutional shareholder, holding 5.48M shares.
2026-07-28 02:42:24
This article provides a technical analysis of Aldeyra Therapeutics Inc (ALDX), detailing its current price momentum score, support and resistance levels, and insights from various technical indicators and moving averages. The stock (ALDX) is currently trading within a range, with indicators showing a mix of buy, sell, and neutral signals, leading to an overall neutral signal based on moving averages and technical indicators.
